Rain oncology stock.

30 May 2023 ... Related Content · East Bay cancer drug maker's stock plummets on trial results · These companies have no drugs yet, but they're still selling hope.On average, Wall Street analysts predict. that Rain Oncology's share price could reach $1.33 by Sep 18, 2024. The average Rain Oncology stock price prediction forecasts a potential upside of 22.29% from the current RAIN share price of $1.09.We would like to show you a description here but the site won’t allow us.1 Jun 2021 ... Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish ...

0.82%. ARM. 3.90%. Get the latest Mural Oncology PLC (MURA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ...

Stock Quote & Chart. Historical Price Lookup. ... Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR ...

Rain Therapeutics Inc. (RAIN) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Add to watchlist 2W 10W 9M 5.76 +0.01 (+0.17%) At close: 04:00PM EST 5.93 +0.17 (+2.95%) After hours: 04:38PM... Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update. Find the latest Rain Oncology Inc. (RAIN) stock quote, history, news and other vital... Oct 20, 2023 · Get Rain Oncology Inc (RAIN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Rain Oncology (NASDAQ: RAIN) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company’s ...Web

1 Jun 2021 ... Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish ...

Non-cash stock-based compensation expense included in G&A expenses were approximately $0.3 million and $1.1 million for the three months and year ended December 31, 2022, respectively, as compared ...

The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.Aug 10, 2023. NEWARK, Calif., August 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. “Rain has been aggressively pursuing a multitude of opportunities as we seek to leverage our clinical execution capabilities and strong cash position to add value to our ...16 Oct 2023 ... Rain Oncology, Inc. ... Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are ...Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...

Stock analysis for Rain Oncology Inc (RAIN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.WebWith stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Description. Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. 22 May 2023 ... Rain's shares tumbled more than 80% Monday morning from a prior close of $9.93 to $1.62 as the biotech announced that development in ...Nov 22, 2023 · Rain Oncology. stock was originally listed at a price of $15.80 in Apr 23, 2021. If you had invested in Rain Oncology stock at $15.80, your return over the last 2 years would have been -93.23%, for an annualized return of -73.98% (not including any dividends or dividend reinvestments). Rain Oncology, Inc. (NASDAQ: RAIN) Class Period: July 20, 2021 - May 19, 2023. ... In response to the announcement, Rain’s stock price substantially dropped from $9.93 per share to $1.22 per share, eliminating approximately $316 million in market capitalization in one day.Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.

20 Jul 2023 ... In response to the announcement, Rain's stock price substantially dropped from $9.93 per share to $1.22 per share, eliminating approximately ...

These are a few biotech companies to watch closely in 2023: Data sources: Yahoo! Finance and company websites. Market caps as of May 19, 2023. Company. Market Capitalization. Primary focus. Axsome ...Rain Oncology Inc. Common Stock (RAIN) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is... Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The shares are being sold at an offering price of $5.83 per ...Complete Rain Oncology Inc. stock information by Barron's. View real-time RAIN stock price and news, along with industry-best analysis. On average, Wall Street analysts predict. that Rain Oncology's share price could reach $1.33 by Sep 18, 2024. The average Rain Oncology stock price prediction forecasts a potential upside of 22.29% from the current RAIN share price of $1.09.WebRain Oncology is a clinical-stage company researching, developing and translating innovative targeted therapies for patients with cancer to help provide them hope to get their lives back. Our ...Web

Rain Oncology ( NASDAQ: RAIN) shed ~9% in the morning hours Tuesday after announcing layoffs, the departure of the company’s chief medical officer, and changes to its clinical programs for lead ...

NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate ...

Exhibit 10.15 FIRST AMENDMENT TO. RAIN THERAPEUTICS INC. 2021. EMPLOYEE STOCK PURCHASE PLAN. WHEREAS, Rain Oncology Inc. (f/k/a Rain Therapeutics Inc.), a Delaware corporation (the “Company”) maintains the Rain Therapeutics Inc. 2021 Employee Stock Purchase Plan (the “Plan”); . WHEREAS, …As of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies ...Find the latest Pyxis Oncology, Inc. (PYXS) stock quote, history, news and other vital information to help you with your stock trading and investing.With the company starting 2023 with 8,725 employees, that’s an 11.5% workforce reduction. Story. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut ...Track Rain Therapeutics Inc (RAIN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsShares of Cullinan Oncology ( CGEM 3.30%) were up as much as 24.3% this week after being as high as 24.9%, according to data provided by S&P Global Market Intelligence. The stock closed last week ...Company's Cash Reserves of $452.6 Million Expected to Fund Operations Until Mid-2026. Find the latest Kura Oncology, Inc. (KURA) stock quote, history, news and other vital information to help you ...Analyst's Opinion · Consensus Rating. Rain Oncology has received a consensus rating of Hold. · Price Target Upside/Downside. According to analysts' consensus ...1 Jun 2021 ... Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish ...The average price target is $1.33 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 20.91% change from the last ...

Nov 24, 2023 · Company Summary. Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product ... Rain Oncology is a late-stage oncology company specializing in precision oncology by targeting oncogenic drivers. Click here to see why the stock is a speculative buy.Relief rain occurs when warm, moist air ascends along the slope of a mountain. The air then condenses and rainfall occurs on the windward side. The leeward side of the mountain receives very little rainfall. This is called the rain shadow r...Of course Rain Oncology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.Instagram:https://instagram. hcm software marketfundrise vs reitsstrongest buy stocksnvda forecast 2023 The global pharmaceutical industry is expected to generate $1.15 trillion in sales in 2023, according to Statista. The oncology segment alone should see $188.2 billion in sales this year. The ... stock xlvcaptive insurance tax benefits View the latest Oncology Pharma Inc. (ONPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.3 analysts have issued 1 year price objectives for Surface Oncology's stock. Their SURF share price targets range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 320.6% from the stock's current price. View analysts price targets for SURF or view … beagle 401k legit RAIN News Today | Why did Rain Oncology stock go up today? S&P 500 4,559.34. DOW 35,390.15. QQQ 389.51. 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas. [Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad) Turned down for a loan, business owners look to family and even ...Success is Achieved Together. Biosimulation can reduce the size of and cost of human trials, the most expensive and time-consuming part of drug development. In some cases, we can eliminate certain human trials completely. More than 2,000 customers worldwide choose us as their partner for biosimulation software and technology-driven services.As of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies ...